1. Home
  2. CSL vs RPRX Comparison

CSL vs RPRX Comparison

Compare CSL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carlisle Companies Incorporated

CSL

Carlisle Companies Incorporated

HOLD

Current Price

$325.74

Market Cap

13.4B

Sector

Industrials

ML Signal

HOLD

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$39.70

Market Cap

16.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSL
RPRX
Founded
1917
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4B
16.2B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CSL
RPRX
Price
$325.74
$39.70
Analyst Decision
Buy
Strong Buy
Analyst Count
6
3
Target Price
$386.67
$46.00
AVG Volume (30 Days)
457.8K
4.3M
Earning Date
10-29-2025
11-05-2025
Dividend Yield
1.36%
2.21%
EPS Growth
N/A
N/A
EPS
17.56
1.75
Revenue
$5,015,100,000.00
$2,349,844,000.00
Revenue This Year
$1.01
$37.13
Revenue Next Year
$2.69
$1.48
P/E Ratio
$18.54
$22.68
Revenue Growth
0.14
3.70
52 Week Low
$293.43
$24.05
52 Week High
$440.73
$41.24

Technical Indicators

Market Signals
Indicator
CSL
RPRX
Relative Strength Index (RSI) 54.88 57.50
Support Level $313.97 $39.24
Resistance Level $324.30 $40.50
Average True Range (ATR) 8.93 0.91
MACD 2.60 -0.08
Stochastic Oscillator 87.75 76.02

Price Performance

Historical Comparison
CSL
RPRX

About CSL Carlisle Companies Incorporated

Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Share on Social Networks: